Premium
Global Biotech goes China – Institut Pasteur Shanghai launches a unique platform for global biotech companies in China
Author(s) -
Altmeyer Ralf
Publication year - 2011
Publication title -
biotechnology journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.144
H-Index - 84
eISSN - 1860-7314
pISSN - 1860-6768
DOI - 10.1002/biot.201100172
Subject(s) - china , thriving , government (linguistics) , intellectual property , political science , microbiology and biotechnology , biology , law , sociology , social science , linguistics , philosophy
peutic areas, with 2.2 million cancer deaths, 170,000 deaths from cardiovascular disease, 90 million diabetics and 140 million chronic carriers of Hepatitis B and C reported in 2009 [3, 4]. Over the counter medicines (OTC) and traditional Chinese medicine still account for a large percentage of sales in the China pharmaceutical market but the market share taken by patented products is increasing rapidly [5]. These products enter a market that is also transformed by the massive healthcare reforms led by the Chinese Ministry of Health, which injected US$ 123bn to create a healthcare system aiming at universal coverage and intellectual property law reforms [6].